RIO DE JANEIRO, BRAZIL – Anvisa (National Health Surveillance Agency) approved on April 25 one more cannabis-based medicinal product in Brazil, the Cannabidiol Active Pharmaceutical. It is the 15th product with commercialization approved in the country.
The product must contain 20 mg/ml of cannabidiol (CBD) and up to 0.2% of tetrahydrocannabinol (THC). Anvisa stated that it would be produced in Canada and marketed in Brazil.
Of the 15 medicinal products already approved by the agency, ten are based on the phytochemical cannabidiol and five on extracts of Cannabis sativa.
Free daily brief — no card needed
Get every Brazil story in one morning email
We build you a personalized brief around the topics you follow — free for 7 days. Love it? Your first month after that is US$1.
Cannabidiol Active Pharmaceutical will be sold in pharmacies and drugstores in Brazil, but only those who have a prescription with type B prescriptions with the blue color will be able to buy it.
Rio Times membership
Read everything we publish for US$1 in the first month.
